MDxHealth (NASDAQ:MDXH) Announces Earnings Results

MDxHealth (NASDAQ:MDXH) posted its earnings results on Wednesday. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.07, Zacks reports. The company had revenue of $24.74 million for the quarter, compared to analyst estimates of $22.67 million. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%.

MDxHealth Stock Down 1.6 %

MDxHealth stock traded down $0.03 during midday trading on Friday, reaching $1.83. The company’s stock had a trading volume of 40,968 shares, compared to its average volume of 101,972. The business has a 50-day simple moving average of $2.01 and a 200-day simple moving average of $2.20. The company has a market cap of $86.54 million, a P/E ratio of -1.20 and a beta of 1.34. MDxHealth has a fifty-two week low of $1.55 and a fifty-two week high of $3.85. The company has a quick ratio of 1.45, a current ratio of 1.54 and a debt-to-equity ratio of 3.14.

Analysts Set New Price Targets

A number of research firms have commented on MDXH. Piper Sandler decreased their target price on shares of MDxHealth from $8.00 to $6.00 and set an “overweight” rating on the stock in a research report on Thursday, November 7th. Lake Street Capital initiated coverage on MDxHealth in a research note on Thursday, October 31st. They issued a “buy” rating and a $7.00 price objective for the company.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.